ClinicalTrials.gg
RecruitingNCT06607627Updated Apr 1, 2026

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

A Phase 3 interventional study of Gefurulimab in Generalized Myasthenia Gravis and gMG, sponsored by Alexion Pharmaceuticals, Inc.. Recruiting at 13 sites in 5 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies in Myasthenia Gravis by AstraZeneca — 8 open to participants now, 11 under way, 4 of them phase 3. Myasthenia Gravis · AstraZeneca.

Planned enrollment
10th of 13
12 · median 20
Started
2024
with 2 others
Phase 3
9 of 19
2 open now
Primary completion
2026-12
later than 2 of 10 live
Registered
12th of 19
by date

Among the 19 studies in Myasthenia Gravis by AstraZeneca, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2024, is one of 9 in phase 3, reaches primary completion later than 2 of the 10 other live ones, and was the 12th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

8 of the 19 studies in Myasthenia Gravis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myasthenia Gravis by AstraZeneca, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.

03

Conditions studied

  • Generalized Myasthenia Gravis
  • gMG

Browse trials for

Keywords

  • Acetylcholine Receptor antibodies
  • AChR+
  • Generalized Myasthenia Gravis
  • gMG
  • ALXN1720
  • anti-acetylcholine receptor antibody-positive
  • acetylcholine receptor
  • AChR
  • myasthenia gravis
  • MG
  • complement component 5
  • C5
  • VHH antibody
  • pediatric
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

United States of America (USA) specific inclusion criterion:

  • Participant must be 12 to \< 18 years of age at the time of signing the /assent.
  • All participants must be vaccinated against meningococcal infection from serogroups A, B, C, W, and Y within 3 years and at least 2 weeks prior to the first dose of study intervention administration.

Rest of World (ROW) specific inclusion criteria:

  • Participant must be 6 to \< 18 years of age at the time of signing the informed consent/assent.
  • All participants must be vaccinated against meningococcal infection from serogroups A, C, W, Y (and B where available) within 3 years prior to study intervention on Day 1. If vaccination occurs \< 2 weeks prior to Day 1, the participants will receive prophylactic antibiotics for at least 2 weeks after initial meningococcal vaccination for serogroups A,C,W,Y (and B, where available)

Global inclusion criteria:

  • Diagnosis of MG with generalized muscle weakness meeting the clinical criteria defined by Myasthenia Gravis Foundation of America (MGFA) Class II, III or IV
  • Positive serological test for autoantibodies against AChR

Exclusion criteria

Exclusion Criteria:

  • History of thymectomy, or any other thymic surgery within 12 months prior to Screening
  • Untreated thymic , carcinoma, or thymoma
  • History of Neisseria meningitidis infection
  • Pregnancy, breastfeeding, or intention to conceive during the course of the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Gefurulimab

    On Day 1, participants will receive a weight based loading dose followed by a weekly maintenance dose for up to 122 weeks.

    Combination Product: Gefurulimab

Interventions

  • Combination productGefurulimab

    Combination product consisting of syringe prefilled with gefurulimab will be administered weekly via subcutaneous (SC) injection.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of Gefurulimab

    Time frame: Day 1 predose through Week 18 predose

  2. Serum Free Complement Component 5 (C5) Concentration

    Time frame: Day 1 predose through Week 18 predose

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    Time frame: Day 1 through Week 134

  2. Change in Quantitative Myasthenia Gravis Score for Disease Severity (QMG) Total Score From Baseline Through Week 18

    Time frame: Baseline through Week 18

  3. Number of Participants With ≥ 5-point Reduction From Baseline in the QMG Total Score Through Week 18

    Time frame: Baseline through Week 18

  4. Change in Myasthenia Gravis Activities of Daily Living Profile (MG-ADL) Total Score From Baseline Through Week 18

    Time frame: Baseline through Week 18

  5. Number of Participants With ≥ 3-point Reduction From Baseline in the MG-ADL Total Score Through Week 18

    Time frame: Baseline through Week 18

  6. Number of Participants With Anti-drug Antibodies (ADAs)

    Time frame: Baseline through Week 134

  7. Number of ADA Positive Participants With Pre-existing Immunoreactivity,Treatment-emergent or Treatment-boosted ADA Responses

    Time frame: Baseline through Week 134

  8. Number of ADA Positive Participants With Neutralizing Antibody (NAb) Positive or Negative Status

    Time frame: Baseline through Week 134

07

Study locations

11 of 13 sites recruiting
  • Research Site
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • Research Site
    Norfolk, Virginia 23507, United States
    Recruiting
  • Research Site
    Joinville, 89202-451, Brazil
    Recruiting
  • Research Site
    Salvador, 41253-190, Brazil
    Recruiting
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
    Recruiting
  • Research Site
    São Paulo, 0438-002, Brazil
    Recruiting
  • Research Site
    São Paulo, 05403-000, Brazil
    Recruiting
  • Research Site
    Saitama-Shi, 330-8777, Japan
    Recruiting
  • Research Site
    Bydgoszcz, 85-065, Poland
    Withdrawn

    Not enrolling at this site.

  • Research Site
    Lodz, 93-338, Poland
    Withdrawn

    Not enrolling at this site.

  • Research Site
    Warsaw, 02-097, Poland
    Recruiting
  • Research Site
    New Taipei City, 23561, Taiwan
    Recruiting
  • Research Site
    Taipei, 11101, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's planned 25 months is close to that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2024
First posted
Sep 23, 2024
StartActual
Nov 13, 2024
Primary completionEst.
Dec 15, 2026
CompletionEst.
Jan 23, 2029
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06607627
Responsible party
Sponsor
First posted
Sep 23, 2024
Start date
Nov 13, 2024
Primary completion
Dec 15, 2026 (estimated)
Completion
Jan 23, 2029 (estimated)
Last update
Apr 1, 2026

Study contacts

Alexion Pharmaceuticals, Inc. (Sponsor)
Contact
clinicaltrials@alexion.com
1-855-752-2356

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gefurulimab

Start the discussion